OncoMatch/Clinical Trials/NCT07281924

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

Is NCT07281924 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Nivolumab and Relatlimab and Melphalan for metastatic melanoma.

Phase 1/2RecruitingUniversity of Wisconsin, MadisonNCT07281924Data as of May 2026

Treatment: Nivolumab and Relatlimab · Melphalan — This study is being done to see if combining HEPZATO KIT™ with nivolumab and relatlimab (Opdualag™) in the first line setting in patients with metastatic melanoma with liver metastasis is safe, tolerable, and will have a synergistic effect leading to improved clinical outcomes compared to the historic cohort of patients with liver metastasis treated with combination immune checkpoint inhibitor therapy.

Check if I qualify

Extracted eligibility criteria

Cancer type

Melanoma

Disease stage

Metastatic disease required

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: (HEPZATO KIT, nivolumab and relatlimab (Opdualag))

Prior treatment with HEPZATO KIT™ or nivolumab and relatlimab (Opdualag™)

Lab requirements

Blood counts

Kidney function

Liver function

Demonstrate adequate organ function; all screening labs to be obtained within 28 days prior to registration.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

UW Hospital and Clinics · Madison, Wisconsin

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify